Nicolet Bankshares Inc. Purchases 959 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Nicolet Bankshares Inc. grew its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 6.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,290 shares of the biopharmaceutical company’s stock after buying an additional 959 shares during the period. Nicolet Bankshares Inc.’s holdings in Bristol-Myers Squibb were worth $739,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. KBC Group NV increased its position in Bristol-Myers Squibb by 14.8% during the 2nd quarter. KBC Group NV now owns 845,708 shares of the biopharmaceutical company’s stock worth $38,353,000 after buying an additional 108,964 shares during the period. Investment Management of Virginia LLC increased its position in shares of Bristol-Myers Squibb by 142.6% in the second quarter. Investment Management of Virginia LLC now owns 146,161 shares of the biopharmaceutical company’s stock worth $6,628,000 after purchasing an additional 85,904 shares during the period. ARK Investment Management LLC increased its position in shares of Bristol-Myers Squibb by 81.4% in the second quarter. ARK Investment Management LLC now owns 352,421 shares of the biopharmaceutical company’s stock worth $15,982,000 after purchasing an additional 158,104 shares during the period. Alpha Windward LLC increased its position in shares of Bristol-Myers Squibb by 8.4% in the second quarter. Alpha Windward LLC now owns 5,375 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 417 shares during the period. Finally, Grimes & Company Inc. increased its position in shares of Bristol-Myers Squibb by 3.8% in the second quarter. Grimes & Company Inc. now owns 171,913 shares of the biopharmaceutical company’s stock worth $7,796,000 after purchasing an additional 6,304 shares during the period. Hedge funds and other institutional investors own 77.71% of the company’s stock.

In other Bristol-Myers Squibb news, insider Karen Murphy Santiago sold 3,065 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $47.56, for a total value of $145,771.40. Following the transaction, the insider now owns 3,066 shares in the company, valued at $145,818.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Robert J. Bertolini bought 11,000 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was acquired at an average price of $44.72 per share, for a total transaction of $491,920.00. Following the transaction, the director now owns 11,397 shares of the company’s stock, valued at $509,673.84. The disclosure for this purchase can be found here. Insiders own 0.13% of the company’s stock.

Bristol-Myers Squibb stock traded up $0.03 during midday trading on Friday, reaching $47.32. The company’s stock had a trading volume of 11,859,166 shares, compared to its average volume of 15,226,683. Bristol-Myers Squibb Co has a 52 week low of $42.48 and a 52 week high of $63.69. The company has a current ratio of 3.88, a quick ratio of 3.75 and a debt-to-equity ratio of 1.51. The firm’s 50-day moving average is $45.40. The firm has a market cap of $77.36 billion, a PE ratio of 11.89, a PEG ratio of 2.34 and a beta of 0.73.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. The firm had revenue of $6.27 billion for the quarter, compared to analysts’ expectations of $6.10 billion. During the same quarter in the previous year, the business posted $1.01 earnings per share. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. Research analysts anticipate that Bristol-Myers Squibb Co will post 4.26 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were given a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 3.47%. The ex-dividend date was Wednesday, July 3rd. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.

A number of research analysts recently commented on BMY shares. Barclays upgraded Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $53.00 to $55.00 in a research report on Friday, May 3rd. Argus cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price target on the stock. in a research report on Monday, May 20th. Goldman Sachs Group started coverage on Bristol-Myers Squibb in a research report on Tuesday, May 28th. They issued a “buy” rating and a $54.00 price target on the stock. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research report on Tuesday, May 7th. Finally, BMO Capital Markets raised their price target on Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $55.34.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: Holder of Record

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.